PTGS2 and chronic myelogenous leukemia, BCR-ABL1 positive: We describe here a comparative transcriptome analysis of CML patients and HC subjects, highlighting the lower expression of HOTAIR and PTGS2 in CML patients, which may be related to disease status and imatinib treatment.